Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02331433 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, and Pharmacokinetics of Single Doses of APN1125 in Healthy Normal Subjects
A Phase 1 study, sponsored by CoMentis.
- Completed
- Registry status
- Phase 1
- Development phase
- 58
- Enrollment target
NCT02331433: Completed Phase 1 study, sponsored by CoMentis.
NCT02331433 is a Phase 1 study that has completed, run by CoMentis. The registered enrollment target is 58 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02331433, a Phase 1 study, has completed, sponsored by CoMentis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 58 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of APN1125 when administered as single doses to healthy adult subjects.
Interventions
- DRUG Placebo
- DRUG APN1125
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2014-12 |
| Est. Completion | 2015-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02331433
The ClinicalTrials.gov registry entry for NCT02331433 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CoMentis, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02331433 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02331433 about?
NCT02331433 is a clinical study titled "Safety, Tolerability, and Pharmacokinetics of Single Doses of APN1125 in Healthy Normal Subjects". The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of APN1125 when administered as single doses to healthy adult subjects.
What is the current status of trial NCT02331433?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 58 participants. The study started on 2014-12. Estimated completion is 2015-12.
What interventions are being tested in trial NCT02331433?
The interventions under investigation include: Placebo (DRUG), APN1125 (DRUG).
Who is sponsoring clinical trial NCT02331433?
This trial is sponsored by CoMentis, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.